Seek Labs Maps High-Burden Mosquito-Borne Infectious Diseases with BioSeeker™, Accelerating Therapeutic Discovery for Chikungunya, West Nile Virus, and Zika
By unlocking targets for Chikungunya, West Nile Virus, and Zika, BioSeeker has compressed years of discovery into weeks, paving the way for programmable, pathogen-specific therapeutics that could be deployed when and where they're needed most.
BioSeeker Powers Precision Genomics for Programmable Therapeutics
BioSeeker™ is Seek Labs' molecular strategist. By scanning thousands of viral and pathogenic genomes, it identifies conserved, high-potential sequences essential to disease survival and replication. These 'genomic weak points' serve as blueprints for Seek Labs' Programmable Target Ablation Platform (PTAP™), which utilizes CRISPR systems to irreversibly disable pathogens with genomic precision. By unlocking targets for Chikungunya, West Nile Virus, and Zika, BioSeeker has compressed years of discovery into weeks, paving the way for programmable, pathogen-specific therapeutics that could be deployed when and where they're needed most.
'Mosquito-borne diseases are among the most complex and under-addressed in global health, spanning diverse pathogens, vectors, and regions with limited therapeutic tools,' said Jared Bauer, CEO of Seek Labs. 'BioSeeker gives us a global vantage point and a tactical advantage: we know where to strike, and we have the tools to do it.'
Global Burden and Urgency
Mosquito-borne viral diseases infect over 400 million people each year and remain some of the most overlooked threats in global and regional public health:
Chikungunya, spread by Aedes mosquitoes, causes chronic joint pain and has resurged in explosive outbreaks across Asia and the Americas.
Zika, also Aedes -borne, is linked to birth defects and neurological disorders, particularly devastating in pregnant individuals.
West Nile Virus is spread primarily by Culex mosquitoes and, while many cases are asymptomatic, severe neuroinvasive disease can result in encephalitis, paralysis, and death, especially among older adults and immunocompromised individuals.
Despite their scale, these diseases have no approved therapeutics in routine use. As vector ranges expand due to shifting climate conditions and urbanization, the window to respond grows narrower and the need for scalable, regionally adaptable solutions is greater. Additionally, recent reports of West Nile Virus in Utah have brought this growing threat even closer to Seek Labs' doorstep, underscoring the importance of local preparedness alongside global response.
A Global Call to Partner in Programmable Therapeutics for Chikungunya, West Nile Virus, and Zika
With pathogen mapping complete and PTAP guide designs ready for validation, Seek Labs is actively seeking development partners to advance these targets into the next generation of programmable infectious disease therapeutics. The company invites mission-aligned collaborators—including biopharma developers, government agencies, and global health organizations—to accelerate this next phase and help redefine what's possible in mosquito-borne disease control.
About Seek Labs
At Seek Labs, we don't wait for change—we build it. We're pursuing the breakthroughs the world can't wait for by developing programmable 'seek-and-destroy' therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. At the core of this mission is a layered architecture: BioSeeker™ serves as the Intelligence Layer, continuously mapping conserved viral vulnerabilities in real time; these insights activate our Deployment Layers (PTAP™ for programmable therapeutics and SeekIt™ for molecular diagnostics), forming a full-stack development engine designed to accelerate response, innovation, and impact across global health.
Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah's collaborative life sciences ecosystem. Together with our partners, we're building faster, smarter solutions for the world's most urgent health challenges.
Forward-Looking Statements and Regulatory Disclaimer
This press release includes forward-looking statements about Seek Labs' technologies, development plans, and partnership opportunities. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ. The technologies described are investigational and have not been reviewed or approved by the FDA or any other regulatory authority for clinical or commercial use.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 minutes ago
- Business Wire
Innovative Industrial Properties Announces Strategic and Diversifying $270 Million Investment in Life Science Real Estate Platform
SAN DIEGO--(BUSINESS WIRE)--Innovative Industrial Properties, Inc. (NYSE: IIPR) ('IIP' or the 'Company'), announced today that it entered into agreements to make an investment totaling up to $270 million into IQHQ, Inc. ('IQHQ'), a premier life science real estate platform with over $5 billion in total assets. The investment (the 'Investment,' 'Transaction,' or 'Investment Transaction') is comprised of two discrete investments that together are expected to earn a weighted average interest rate of greater than 14% per annum: A $100 million commitment to a revolving credit facility ('RCF') with an initial term of three years, which can be extended for an additional 12 months upon payment of an extension fee. The RCF will be fully funded upfront, with closing subject to customary approvals. A commitment to purchase up to $170 million of preferred stock ('Preferred Stock') of IQHQ. The Preferred Stock investment is expected to be funded in multiple tranches between the third quarter of 2025 and the second quarter of 2027, subject to extensions at the option of IQHQ. Warrants in IQHQ, subject to the satisfaction of certain funding milestones of the Preferred Stock. 'We are excited to announce our first expansion outside of cannabis with this highly accretive transaction that diversifies our business and accelerates IIP's growth trajectory,' said Alan Gold, Executive Chairman of IIP. 'While we remain committed to the cannabis industry, this transaction leverages our team's deep historical experience in the life science industry, which we believe will benefit IIP shareholders via earnings growth and as participants in the life science secular recovery that I believe is underfoot. The transaction is structured with key tenets that include strong current income over the life of the investment, paired with future upside opportunities via warrants and the potential to acquire life science real estate facilities directly from IQHQ.' Strategic and Financial Benefits of the Transaction: Highly Accretive Transaction Investment is expected to be highly accretive to AFFO per share based on the weighted average interest rate payable (which is expected to exceed 14% per annum). Senior Position in the Capital Stack Offers Strong Risk-Adjusted Return Opportunity Investment is comprised of the RCF and Preferred Stock, which both sit senior to all common equity in IQHQ and at a material discount to replacement cost of the underlying assets. Enhanced Portfolio Diversification by Sector, Tenant and Investment Type Pro forma for the closing of the Transaction, IIP will diversify its holdings and reduce current sector and tenant concentration. IIP believes these measures further improve its financial outlook. Rental revenues from regulated cannabis facilities are expected to decrease to 88% of the Company's total revenues on an adjusted basis as of June 30, 2025. Improved Cost of Capital Potential The enhanced scale and diversification that is expected from the Transaction may support a lower cost of equity and debt capital for IIP and further accelerate its growth. IIP has Expertise in Capitalizing on Long-Term Secular Tailwinds in Life Sciences IIP management team has decades of combined experience in the life science real estate industry through its prior role leading top-performing publicly-traded life science REITs. Noteworthy experience includes Alan Gold's role as Founder and CEO of BioMed Realty Trust, which held its IPO in 2004 and culminated in a successful $8 billion sale to Blackstone in 2016. According to Pitchbook, 2025 fundraising for the life science industry is on track to achieve the highest level since 2021, which was the all-time high. According to CBRE, deliveries of new life science real estate are expected to meaningfully decrease during the term of the Transaction, which IIP believes will contribute to strength in the underlying sector and Investment. The Company expects to fund the RCF with a combination of cash on hand and draws from the Company's revolving credit facility. The Company expects to fund the Preferred Stock investment with cash on hand, draws from the Company's revolving credit facility and potential proceeds from future financing activities. The Investment Transaction is expected to close in the third quarter of 2025, subject to the satisfaction of customary closing conditions. About IQHQ IQHQ, Inc. is a life science focused real estate company founded in 2019 to meet the growing industry needs through the acquisition, development, redevelopment, leasing and management of life science assets. About Innovative Industrial Properties Innovative Industrial Properties, Inc. is a real estate investment trust (REIT) focused on the acquisition, ownership and management of specialized industrial properties, and, pro forma for this contemplated transaction, life science real estate. Additional information is available at This press release contains statements that IIP believes to be 'forward-looking statements' within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than historical facts are forward-looking statements. When used in this press release, words such as IIP 'expects,' 'intends,' 'plans,' 'estimates,' 'anticipates,' 'believes' or 'should' or the negative thereof or similar terminology are generally intended to identify forward-looking statements, and they include, but are not limited to, statements regarding the size, structure, and timing of the Investment Transaction; its expected yield and accretive impact; the satisfaction of closing conditions; anticipated effects on the Company's financial results, including AFFO per share; expected improvements in cost of capital and future growth prospects; anticipated funding sources for the Preferred Stock investment; the outlook for the life science industry; and potential upside from the receipt of warrants. These forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, such statements. Factors that could cause results to differ from those projected or assumed in any forward-looking statement include, but are not limited to, the risk factors discussed in the Company's most recent Annual Report on Form 10-K for the year ended December 31, 2024, as updated by the Company's subsequent reports filed with the Securities and Exchange Commission. Investors should not place undue reliance upon forward-looking statements. IIP disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Business Wire
4 minutes ago
- Business Wire
Informa TechTarget to Announce Q2 2025 Financial Results on August 12, 2025
NEWTON, Mass.--(BUSINESS WIRE)--TechTarget, Inc. (Nasdaq: TTGT) ('Informa TechTarget' or the 'Company'), a leading growth accelerator for the B2B Technology sector, today announced that it will release its Q2 2025 financial results for the three months ended June 30, 2025 before the market opens on Tuesday, August 12, 2025. The Company's Chief Executive Officer, Gary Nugent, and Chief Financial Officer, Dan Noreck, will host a live conference call and webcast at 8:30 a.m. Eastern Time on that day to discuss the Company's financial results and outlook. The Q2 2025 financial results will be available prior to the conference call and webcast on the investor relations section of the Company's website at Conference Call Dial-In Information: United States (Toll Free): 1-833-470-1428 United States: 1-404-975-4839 United Kingdom (Toll Free): +44 808 189 6484 United Kingdom: +44 20 8068 2558 Global Dial-in Numbers Access code: 967110 Please access the call at least 10 minutes prior to the time the conference is set to begin. Please ask to be joined into the Informa TechTarget call. Conference Call Webcast Information: This webcast can be accessed via Informa TechTarget's website at Conference Call Replay Information: A replay of the conference call will be available via telephone beginning one (1) hour after the conference call through September 11, 2025 at 11:59 p.m. ET. To hear the replay: United States (Toll Free): 1-866-813-9403 United States: 1-929-458-6194 Access Code: 703085 A web version will also be available for replay during the same period on Informa TechTarget's website at About Informa TechTarget TechTarget, Inc. (Nasdaq: TTGT), which also refers to itself as Informa TechTarget, informs, influences and connects the world's technology buyers and sellers, helping accelerate growth from R&D to ROI. With a vast reach of over 220 highly targeted technology-specific websites and over 50 million permissioned first-party audience members, Informa TechTarget has a unique understanding of and insight into the technology market. Underpinned by those audiences and their data, we offer expert-led, data-driven, and digitally enabled services that have the potential to deliver significant impact and measurable outcomes to our clients: Trusted information that shapes the industry and informs investment Intelligence and advice that guides and influences strategy Advertising that grows reputation and establishes thought leadership Custom content that engages and prompts action Intent and demand generation that more precisely targets and converts Informa TechTarget is headquartered in Boston, MA and has offices in 19 global locations. For more information, visit and follow us on LinkedIn. © 2025 TechTarget, Inc. All rights reserved. All trademarks are the property of their respective owners.
Business Wire
4 minutes ago
- Business Wire
Apple and Corning partner to manufacture 100 percent of iPhone and Apple Watch cover glass in Kentucky
CUPERTINO, Calif.--(BUSINESS WIRE)--Apple® and Corning today announced a major expansion of their long-standing partnership to make precision glass for Apple products. Apple is making a new $2.5 billion commitment to produce all of the cover glass for iPhone® and Apple Watch® in Corning's Harrodsburg, Kentucky, manufacturing facility. This means that 100 percent of the cover glass on iPhone and Apple Watch units sold worldwide will be made in the U.S. for the first time. Corning is creating the world's largest and most advanced smartphone glass production line at the Harrodsburg facility. Corning will now dedicate this entire facility to manufacturing for Apple, which will help increase Corning's manufacturing and engineering workforce in Kentucky by 50 percent. The two companies will also open a new Apple-Corning Innovation Center at the Harrodsburg plant. The Innovation Center will play a key role in the development and engineering of advanced materials and next-generation manufacturing platforms for Apple's future generations of products. These projects are part of Apple's broader commitment to spend and invest more than $600 billion in the U.S. economy over the next four years. This includes Apple's newly announced American Manufacturing Program (AMP), which will invest across America and incentivize global companies to onshore production and manufacture even more of Apple's critical components in the United States. 'Corning is a storied American company, and we're thrilled to work together to build the largest and most advanced production line ever created for smartphone glass,' said Tim Cook, Apple's CEO. 'Thanks to the power of American manufacturing, any customer anywhere in the world who buys a new iPhone or Apple Watch will be holding precision glass made right here in Kentucky. We're grateful to the President and his administration for their support for American manufacturing, and we're excited for the innovation this investment will unlock.' 'Apple is an amazing partner for American manufacturers like us, and together, we've innovated and pushed the boundaries of what's possible,' said Wendell Weeks, Corning's CEO. 'We developed and made the glass for the very first iPhone in Harrodsburg, Kentucky, 18 years ago. With this new multibillion-dollar commitment from Apple and the lighting of our most advanced manufacturing platform, we are hiring more people and bringing 100 percent of Apple's cover glass needs for iPhone and Apple Watch to the original home of the innovation.' This announcement continues a partnership that has been in place between Apple and Corning since the launch of the original iPhone in 2007. Today, the Harrodsburg, Kentucky, facility produces high-quality glass for Apple called Ceramic Shield®. This advanced glass — the toughest in any smartphone — is the result of years of innovation by Apple and Corning engineers working closely together. Since the creation of Apple's U.S. Advanced Manufacturing Fund in 2017, Apple has invested nearly $500 million in Corning's Kentucky operations, with billions more spent on glass manufactured in the U.S. Corning also provides raw materials used by another AMP company, GlobalWafers, which will use silicon from Corning to manufacture advanced bare wafers in the U.S. for the first time. In that way, Corning also plays a key role in Apple's supply chain for producing advanced silicon chips in America. Apple has a long history of investing in the U.S., creating opportunity and driving American innovation. Today, Apple partners with thousands of suppliers across all 50 states, supporting more than 450,000 supplier and partner jobs. In the next four years, Apple plans to directly hire 20,000 people in the U.S. — the vast majority focused on R&D, silicon engineering, software development, and AI and machine learning. Apple revolutionized personal technology with the introduction of the Macintosh in 1984. Today, Apple leads the world in innovation with iPhone, iPad, Mac, AirPods, Apple Watch, and Apple Vision Pro. Apple's six software platforms — iOS, iPadOS, macOS, watchOS, visionOS, and tvOS — provide seamless experiences across all Apple devices and empower people with breakthrough services including the App Store, Apple Music, Apple Pay, iCloud, and Apple TV+. Apple's more than 150,000 employees are dedicated to making the best products on earth and to leaving the world better than we found it. NOTE TO EDITORS: For additional information visit Apple Newsroom ( or email Apple's Media Helpline at © 2025 Apple Inc. All rights reserved. Apple, the Apple logo, iPhone, Apple Watch, and Ceramic Shield are trademarks of Apple. Other company and product names may be trademarks of their respective owners.
